Cigna Group (CI) has put Evernorth's US$100 million Pharmacy Forward program at the center of its story, using AI to streamline specialty pharmacy operations as the stock trades at what screens as a discounted P/E.

Over the past year, Cigna Group has combined a modest 2.82% 90-day share price return with a weaker 1-year total shareholder return of an 8.10% decline. This suggests that momentum is only gradually rebuilding as investors weigh index removals against the AI driven Evernorth story and a discounted earnings multiple.

If you are interested in how AI is reshaping healthcare beyond Cigna Group, this is a useful moment to scan for other opportunities in 40 healthcare AI stocks

With Cigna Group trading below both its own estimated fair value and the average analyst price target even after the recent index removals, is this simply caution about PBM and AI execution risks, or an overdone discount?

Most Popular Narrative: 17.3% Undervalued

The most followed Cigna Group narrative anchors fair value at $340.92, above the last close at $281.98. This frames today’s gap as a valuation question rather than a story problem.

Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent; the double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth.

Want to see what sits behind that specialty pharmacy push and the implied fair value for Cigna Group? The narrative leans heavily on projected revenue expansion, firmer margins and a future earnings multiple that assumes investors keep paying for this mix of health services, PBM scale and capital returns. The precise balance of those levers is only clear when you see the full forecast path.

Result: Fair Value of $340.92 (UNDERVALUED)

However, Cigna Group still faces meaningful PBM regulatory pressure and execution risk around the Evernorth transition, as well as potential pushback on pricing as affordability concerns build.

Next Steps

If the mix of risks and rewards around Cigna Group feels finely balanced, move quickly to test the numbers and sentiment for yourself with 6 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cigna Group?

If Cigna Group has caught your attention, do not stop here. Broaden your watchlist and pressure test your thesis against other stocks that fit clear, data driven filters.

• Target potential value opportunities by scanning 41 high quality undervalued stocks that pair earnings power with what screens as discounted prices.
• Prioritize resilience by reviewing 74 resilient stocks with low risk scores that score well on financial strength and lower historical risk signals.
• Hunt for future leaders by checking the screener containing 18 high quality undiscovered gems before the crowd focuses on them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.